If frontline therapies do not produce a full response, will ASCT do so?

 

In this week’s video, Dr. Brian Durie answers a patient’s concern about when and if to undergo an ASCT.

BOTTOM LINE:
Talk to your doctors about all the risks versus benefits of an ASCT in your case.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org